Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma
18h agoen
From the article
Conditions : Oral Squamous Cell Carcinoma (OSCC) Interventions : Other: Saliva Collection and Biomarker Analysis Sponsors : University of Pavia Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Oral Microbes Linked to Increased Risk of Pancreatic Cancer
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·6d ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·6d ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·6d ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·6d ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·6d ago
Using AI to improve cancer immunotherapy outcomes, via training from transcriptomes of 10,000 tumor samples, 33 cancer types @NatureMedicine
nature.com·6d ago

Llamar al cáncer de próstata de bajo riesgo de otra forma podría salvar más vidas, argumentan investigadores
Infobae·2d ago

Study finds cancer-associated somatic mutations in brain immune cells linked to Alzheimer's neuroinflammation
This study investigates the link between Alzheimer's disease (AD) and somatic mutations in brain immune cells. Deep sequencing of 311 brain
cell.com·16d ago
Modellprojekt mit vorbereitendem Workshop zur Implementierung und Evaluierung einer Interventionsstrategie zur Verbesserung der Arzneimitteltherapiesicherheit (AMTS) bei Patientinnen und Patienten mit oraler Tumortherapie
bundesgesundheitsministerium.de·4h ago

Comments
Sign in to join the conversation.
No comments yet. Be the first.